Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PegIntron/Ribavirin Treatment Duration in Genotype 1 HCV
NCT00202839Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2005
- Primary completion
- Jul 2008
- Modality
- Polymer-based Nanoparticles, Orthosteric Ligands, Cytokines & Interferons
01
Overview
Phase 4, randomised, open-label trial of peginterferon alfa-2b and ribavirin in hepatitis C (HCV) (2 arms), sponsored by Merck & Co. Primary endpoint: Sustained Virologic Response. Started Mar 2005; status: completed.
02
Drugs
peginterferon alfa-2bribavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00202839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00202839.